Eli Lilly Acquires Ajax Therapeutics for $2.3B to Boost Oncology Pipeline

Eli Lilly (NYSE: LLY) announced the acquisition of Ajax Therapeutics, a private oncology-focused company, for up to $2.3 billion. The deal aims to strengthen Lilly's oncology pipeline by adding a novel JAK2 inhibitor targeting myeloproliferative neoplasms (MPN). The transaction is expected to close in the second half of 2026.

Deal Details

• Total Value: Up to $2.3 billion, including an upfront payment and future milestone payments tied to regulatory and commercial achievements.
• Primary Asset: Ajax's oral JAK2 inhibitor, which has shown promising results in treating myelofibrosis and other MPNs.
• Payment Method: Cash.
• Premium: Not disclosed.

Rationale

Eli Lilly seeks to expand its presence in hematologic oncology. The JAK2 inhibitor addresses a significant unmet need in MPN, where treatment options are limited. This acquisition follows several other oncology deals by Lilly, reflecting its strategy to diversify revenue streams.

Regulatory Challenges

The deal will likely be reviewed by the U.S. Federal Trade Commission (FTC) and possibly other regulators. Since Ajax is private and the deal does not create major horizontal overlap, significant regulatory hurdles are not anticipated.

Impact on Stocks

LLY stock showed minimal movement following the announcement, as the deal's value is relatively small compared to Lilly's market cap of over $800 billion. However, investors may view the acquisition positively long-term if the JAK2 inhibitor succeeds in the market.